Showing 1011-1020 of 1148 results for "".
Oral Disease Modifying Therapy for MS: Important Considerations
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/oral-disease-modifying-therapy-for-ms-important-considerations/30827/The availability of an oral agent for MS may create a therapeutic dilemma for clinicians as they try to determine the role of new therapy in patient care.Expert Opinion: A Review of the Evaluation and Treatment of Heel Pain, Part 2
https://practicalneurology.com/diseases-diagnoses/headache-pain/expert-opinion-a-review-of-the-evaluation-and-treatment-of-heel-pain-part-2/30545/A panel of specialists review various diagnoses for heel pain in follow-up to last month's overview of heel pain assessment.- Explore the New Practical Neurology Website – Now with CME!https://practicalneurology.com/news/explore-the-new-practical-neurology-website-now-with-cme/2473924/Today, Practical Neurology—an open-access, peer-reviewed journal publishing review articles and case reports to advance neurologic care—is excited to launch a redesigned website at
- FDA Approves Neonatal Fc Receptor Blocker Treatment for Individuals with Generalized Myasthenia Gravishttps://practicalneurology.com/news/fda-approves-neonatal-fc-receptor-blocker-treatment-for-individuals-with-generalized-myasthenia-gravis/2474395/The Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab; Johnson & Johnson, New Brunswick, NJ) for the treatment of individuals aged >12 years with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK)
- Can -Gepants Do It All For Migraine?https://practicalneurology.com/news/can-gepants-do-it-all-for-migraine/2469567/The -gepants are a new class of small molecule antagonists of calcitonin gene-related peptide receptor (CGRP) medications. There is growing evidence that, like the monoclonal antibodies to CGRP or its receptor, the -gepants can prevent migraine when taken regularly. There are 2 -gepants already a
- Zolgensma Approved and Available to Treat All Types of Spinal Muscular Atrophy in Babies Under Age 2 Yearshttps://practicalneurology.com/news/zolgensma-approved-and-available-to-treat-all-types-of-spinal-muscular-atrophy-in-babies-under-age-2-years/2468911/The Food and Drug Administration (FDA) has approved onasemnogene abeparvovac-xioi (Zolgensma; Avexis, Bannockburn, IL) for the treatment of all types of spinal muscular atrophy (SMA) in children under age 2 years. Approved indications for onasemnogene, an SMN gene-replacement therapy, include all
- Shine Forward with Dravet, Support Resource for Parents of Children Living with Dravet Syndrome Launchedhttps://practicalneurology.com/news/shine-forward-with-dravet-support-resource-for-parents-of-children-living-with-dravet-syndrome-launched/2469264/A new resource for parents of children with Dravet syndrome (DS), Shine Forward with Dravethas been launched by pharmaceutical company Zogenix (Emeryville, CA). The website includes a unique set of online tips, tools, and advice from families and is designed to inspire deeper connections between
- Parkinson’s IQ + You Events Provide Support for All Affected by the Disorderhttps://practicalneurology.com/news/parkinsons-iq-you-events-support-provide-support-for-all-affected-by-the-disorder/2468940/A series of events titled Parkinson’s IQ + You will be taking place at locations across the US throughout 2019 and 2020. These events are designed to help people with Parkinson's disease (PD) and their care partners manage the effects of PD, learn about research, and connect with local
- New Patient Resource-86 Migraine-Busts Myths About Migraine and Urges People to Take Back Controlhttps://practicalneurology.com/news/new-patient-resource-86-migraine-busts-myths-about-migraine-and-urges-people-to-take-back-control/2469431/A new website, 86 Migraine (86migraine.org), with the goal of helping individuals with migraine bust myths, cancel--or 86, as they say in the service industry, and have more control over their lives launched today. The website is produced by the Glob
- Addressing Modifiable Risk Factors of Alzheimer Disease Is Effective for All and Has Greater Impact in Womenhttps://practicalneurology.com/news/addressing-modifiable-risk-factors-of-alzheimer-disease-is-effective-for-all-and-has-greater-impact-in-women/2469896/In the CEDAR study (NCT03687710), clinical interventions designed to reduce risk factors for Alzheimer disease (AD) improved cognition for both individuals with and without cognitive impairment at baseline. Further analysis of data fro